Your browser doesn't support javascript.
loading
Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
Vangapandu, Hima V; Jain, Nitin; Gandhi, Varsha.
Affiliation
  • Vangapandu HV; a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
  • Jain N; b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
  • Gandhi V; a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Expert Opin Investig Drugs ; 26(5): 625-632, 2017 May.
Article in En | MEDLINE | ID: mdl-28388280
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Leukemia, Lymphocytic, Chronic, B-Cell / Isoquinolines / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Leukemia, Lymphocytic, Chronic, B-Cell / Isoquinolines / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2017 Document type: Article Affiliation country: United States